Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Invest New Drugs
; 39(6): 1587-1597, 2021 12.
Article
en En
| MEDLINE
| ID: mdl-34180037
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pirrolidinas
/
Para-Aminobenzoatos
/
Neoplasias
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2021
Tipo del documento:
Article